Neurotoxicity secondary to antineoplastic drugs
Tóm tắt
Từ khóa
Tài liệu tham khảo
Kaplan, 1982, Neurotoxicity of antineoplastic drugs, Semin. Oncol., 9, 103
Weiss, 1974, Neurotoxicity of commonly used antineoplastic agents (first of two parts), N. Engl. J. Med., 291, 75, 10.1056/NEJM197407112910205
Weiss, 1974, Neurotoxicity of commonly used antineoplastic agents (second of two parts), N. Engl. J. Med., 291, 127, 10.1056/NEJM197407182910305
Vassal, 1990, Dose-dependent neurotoxicity of high-dose busulfan in children: A clinical and pharmacological study, Cancer Res., 50, 6203
Kalifa, 1992, High-dose busulfan and thiotepa with autologous bone marrow transplantation in childhood malignant brain tumors: A phase II study, Bone Marrow Transplant., 9, 227
Madajewicz, 1981, Phase II study, 47, 653
Sandler, 1969, Vincristine-induced neuropathy, Neurology, 19, 67
Casey, 1973, Vincristine neuropathy, clinical and electrophysiological observations, Brain, 96, 69, 10.1093/brain/96.1.69
Maloney, 1986, Vincristine neurotoxicity [letter], Med. J. Aust., 144, 51, 10.5694/j.1326-5377.1986.tb113639.x
McCarthy, 1991, A prospective cohort study of the orofacial effects of vincristine neurotoxicity, J. Oral Pathol. Med., 20, 345, 10.1111/j.1600-0714.1991.tb00942.x
Legha, 1986, Vincristine neurotoxicity, 1, 421
Davies, 1985, Acute vincristine neurotoxicity [letter], Lancet, 1, 637
Holland, 1973, Vincristine treatment of advanced cancer: a cooperative study of 392 cases, Cancer Res., 33, 1258
Delaney, 1982, Vincristine-induced laryngeal nerve paralysis, Neurology, 32, 1285, 10.1212/WNL.32.11.1285
Griffiths, 1986, Vincristine neurotoxicity enhanced in combination chemotherapy including both teniposide and vincristine, Cancer Treat. Rep., 70, 519
Arnold, 1985, Acute vincristine-neurotoxicity [letter], Lancet, 1, 346, 10.1016/S0140-6736(85)91124-9
Byrd, 1981, Transient cortical blindness secondary to vincristine therapy in childhood malignancies, Cancer, 47, 37, 10.1002/1097-0142(19810101)47:1<37::AID-CNCR2820470108>3.0.CO;2-8
Hurwitz, 1988, Reversible encephalopathy and seizures as a result of conventional vincristine administration, Med. Pediatr. Oncol., 16, 216, 10.1002/mpo.2950160313
Wheeler, 1983, Vincristine-induced bladder neuropathy, J. Urol., 130, 342, 10.1016/S0022-5347(17)51141-6
Carmichael, 1970, Orthostatic hypotension during vincristine therapy, Arch. Intern. Med., 126, 290, 10.1001/archinte.126.2.290
Di Bella, 1980, Vincristine-induced orthostatic hypotension: A prospective clinical study, Cancer Treat. Rep., 64, 359
Roca, 1985, Vinca alkaloid-induced cardiovascular autonomic neuropathy, Cancer Treat. Rep., 69, 149
Mahajah, 1981, Acute acoustic nerve palsy associated with vincristine therapy, Cancer, 47, 2404, 10.1002/1097-0142(19810515)47:10<2404::AID-CNCR2820471014>3.0.CO;2-2
Ripss, 1984, Functional abnormalities in vincristineinduced night blindness, Invest. Ophthalmol. Vis. Sci., 25, 787
Dallera, 1984, Unilateral seizures following vincristine intravenous injection, Tumori, 70, 243, 10.1177/030089168407000307
Hogan-Dann, 1984, Polyneuropathy following vincristine therapy in two patients with Charcot-Marie-Tooth syndrome, JAMA, 252, 2862, 10.1001/jama.252.20.2862
Dickerhoff, 1988, Severe vincristine neurotoxicity in a patient with Charcot-Marie-Tooth disease, Pediatr. Hematol. Oncol., 5, 61, 10.3109/08880018809031253
McGuire, 1989, Acute vincristine neurotoxicity in the presence of hereditary motor and sensory neuropathy type I, Med. Pediatr. Oncol., 17, 520, 10.1002/mpo.2950170534
Norman, 1987, Vincristine neuropathy and a Guillain-Barre syndrome: A case with acute lymphatic leukemia and quadriparesis, Eur. J. Haematol., 39, 75, 10.1111/j.1600-0609.1987.tb00168.x
Thant, 1982, Possible enhacement of vincristine neuropathy by VP 16, Cancer, 49, 859, 10.1002/1097-0142(19820301)49:5<859::AID-CNCR2820490506>3.0.CO;2-9
Warren, 1977, Drug interactions with antineoplastic agents, Cancer Treat. Rep., 61, 1231
Jackson, 1983, Lack of potentiation of vincristine-induced neurotoxicity by VP 16–213, Am. J. Clin. Oncol., 6, 327, 10.1097/00000421-198306000-00013
Jackson, 1986, Clinical trial of folinic acid to reduce vincristine neurotoxicity, Cancer Chemother. Pharmacol., 17, 281, 10.1007/BF00256700
Jackson, 1986, Clinical trial of pyridoxine to reduce vincristine neurotoxicity, J. Neurooncol., 4, 37, 10.1007/BF02158000
Jackson, 1988, Amelioration of vincristine neurotoxicity by glutamic acid, Am. J. Med., 84, 1016, 10.1016/0002-9343(88)90306-3
Sahenk, 1987, Studies on the pathogenesis of vincristine-induced neuropathy, Muscle Nerve, 10, 80, 10.1002/mus.880100115
Krikorian, 1991, Vinorelbine (Navelbine), 14, 7
Marty, 1989, Advances in vinca-alkaloids: Navelbine, Nouv. Rev. Fr. Hematol., 31, 77
Binet, 1989, In situ analysis of the action of Navelbine on various types of microtubules using immunofluorescence, Semin. Oncol., 16, 5
Bleyer, 1981, Neurologic sequelae of methotrexate and ionizing radiation: a new classification, Cancer Treat. Rep., 65, 89
Gasser, 1982, Neurologic and cardiac toxicity following iv application of methotrexate, Cancer Treat. Rep., 66, 1561
Jaffe, 1985, Transient neurologic disturbances induced by high-dose methotrexate treatment, Cancer, 56, 1356, 10.1002/1097-0142(19850915)56:6<1356::AID-CNCR2820560623>3.0.CO;2-H
Packer, 1983, High dose systemic methotrexate-associated acute neurologic dysfunction, Med. Pediatr. Oncol., 11, 159, 10.1002/mpo.2950110304
Walker, 1986, Transient cerebral dysfunction secondary to high-dose methotrexate, J. Clin. Oncol., 4, 1845, 10.1200/JCO.1986.4.12.1845
Rosen, 1979, Primary osteogenic sarcoma, 43, 2163
Fritsch, 1984, Transient encephalopathy during the late course of treatment with high-dose methotrexate, Cancer, 53, 1849, 10.1002/1097-0142(19840501)53:9<1849::AID-CNCR2820530909>3.0.CO;2-6
Martino, 1984, Transient neurologic dysfunction following moderate-dose methotrexate for undifferentiated lymphoma, Cancer, 54, 2003, 10.1002/1097-0142(19841101)54:9<2003::AID-CNCR2820540936>3.0.CO;2-R
Allen, 1980, Leukoencephalopathy following high-dose iv methotrexate chemotherapy with leucovorin rescue, Cancer Treat. Rep., 64, 1261
Phillips, 1987, Reduced cerebral glucose metabolism and increased brain capillary permeability following high-dose methotrexate chemotherapy: a positron emission tomographic study, Ann. Neurol., 21, 59, 10.1002/ana.410210111
Phillips, 1986, Acute high-dose methotrexate neurotoxicity in the rat, Ann. Neurol., 20, 583, 10.1002/ana.410200505
Nelson, 1981, Intrathecal methotrexate-induced neurotoxicities, Am. J. Hosp. Pharm., 38, 65
Ten Hoeve, 1988, A lethal neurotoxic reaction after intraventricular methotrexate administration, Cancer, 62, 2111, 10.1002/1097-0142(19881115)62:10<2111::AID-CNCR2820621007>3.0.CO;2-V
Geiser, 1975, Adverse effects of intrathecal methotrexate in children with acute leukemia in remission, Blood, 45, 189
Duttera, 1973, Irradiation, methotrexate toxicity, and the treatment of meningeal leukemia, Lancet, 2, 703, 10.1016/S0140-6736(73)92539-7
Ulukutlu, 1983, Paraplegia after intrathecal administration of methotrexate, Turk. J. Pediatr., 25, 167
Kay, 1972, Encephalopathy in acute leukemia associated with methotrexate therapy, Arch. Dis. Child., 47, 344, 10.1136/adc.47.253.344
Skullerud, 1978, Encephalomyelopathy following intrathecal methotrexate treatment in a child with acute leukemia, Cancer, 42, 1211, 10.1002/1097-0142(197809)42:3<1211::AID-CNCR2820420326>3.0.CO;2-X
Gagliano, 1976, Paraplegia following intrathecal methotrexate: report of a case and review of the literature, Cancer, 37, 1663, 10.1002/1097-0142(197604)37:4<1663::AID-CNCR2820370408>3.0.CO;2-7
Ojeda, 1982, Necrotising leucoencephalopathy associated with intrathecal/intraventricular methotrexate therapy, Med. J. Aust., 2, 189, 10.5694/j.1326-5377.1982.tb124393.x
Packer, 1981, Focal encephalopathy following methotrexate therapy, Arch. Neurol., 38, 450, 10.1001/archneur.1981.00510070084016
Colamaria, 1990, Transient focal leukoencephalopathy following intraventricular methotrexate and cytarabine, 6, 231
Bleyer, 1978, The Ommaya reservoir, 41, 2431
Poskitt, 1988, Methotrexate leukoencephalopathy mimicking cerebral abscess on CT brain scan, Childs Nerv. Syst., 4, 119, 10.1007/BF00271394
Gilbert, 1989, Methotrexate neurotoxicity: in vitro studies using cerebellar explants from rats, Cancer Res., 49, 2502
Shibutani, 1989, Experimental study on subacute neurotoxicity of methotrexate in cats, Acta Neuropathol. Berl., 78, 291, 10.1007/BF00687759
Cersosimo, 1987, Acute cerebellar syndrome, conjunctivitis, and hearing loss associated with low-dose cytarabine administration, Drug Intell. Clin. Pharm., 21, 798, 10.1177/106002808702101007
Scherokman, 1985, Brachial plexus neuropathy following highdose cytarabine in acute monoblastic leukemia, Cancer Treat. Rep., 69, 1005
Borgeat, 1986, Peripheral neuropathy associated with high-dose Ara-C therapy, Cancer, 58, 852, 10.1002/1097-0142(19860815)58:4<852::AID-CNCR2820580408>3.0.CO;2-I
Sylvester, 1987, Cytarabine-induced cerebellar syndrome: case report and literature review, Drug Intell. Clin. Pharm., 21, 177
Watson, 1985, Severe central nervous system toxicity from high-dose cytarabine: expressive aphasia occuring after the second day of treatment, Cancer Treat. Rep., 69, 313
Salinsky, 1983, Acute cerebellar dysfunction with high-dose Ara-C therapy, Cancer, 51, 426, 10.1002/1097-0142(19830201)51:3<426::AID-CNCR2820510312>3.0.CO;2-S
Lazarus, 1981, Central nervous system toxicity of high-dose systemic cytosine arabinoside, Cancer, 48, 2577, 10.1002/1097-0142(19811215)48:12<2577::AID-CNCR2820481207>3.0.CO;2-Z
Winkelman, 1983, Cerebellar degeneration caused by high-dose cytosine arabinoside: a clinicopathological study, Ann. Neurol., 14, 520, 10.1002/ana.410140505
Barnett, 1985, Central nervous system toxicity of high-dose cytosine arabinoside, Semin. Oncol., 12, 227
Nand, 1986, Neurotoxicity associated with systemic high-dose cytosine arabinoside, J. Clin. Oncol., 4, 571, 10.1200/JCO.1986.4.4.571
Hasle, 1990, Cerebellar toxicity during cytarabine therapy associated with renal insufficiency, Cancer Chemother. Pharmacol., 27, 76, 10.1007/BF00689281
Dworkin, 1985, Cerebellar toxicity following high-dose cytosine arabinoside, J. Clin. Oncol., 3, 613, 10.1200/JCO.1985.3.5.613
Hwang, 1985, Central nervous system toxicity with high-dose Ara-C, Neurology, 35, 1475, 10.1212/WNL.35.10.1475
Lopez, 1984, Acute cerebellar toxicity after high-dose cytarabine associated with CNS accumulation of its metabolite, uracil arabinoside, Cancer Treat. Rep., 68, 1309
Gottlieb, 1987, The neurotoxicity of high-dose cytosine arabinoside is age-related, Cancer, 60, 1439, 10.1002/1097-0142(19871001)60:7<1439::AID-CNCR2820600705>3.0.CO;2-F
Damon, 1989, The association between high-dose cytarabine neurotoxicity and renal insufficiency, J. Clin. Oncol., 7, 1563, 10.1200/JCO.1989.7.10.1563
Hahn, 1983, Paraparesis following intrathecal chemotherapy, Neurology, 33, 1032, 10.1212/WNL.33.8.1032
Dunton, 1986, Progressive ascending paralysis following administration of intrathecal and intravenous cytosine arabinoside, 57, 1083
Crawford, 1986, Acute neurological toxicity of intrathecal cytosine arabinoside: A case report, Cancer Chemother. Pharmacol., 16, 306, 10.1007/BF00293998
Kleischmidt-Demasters, 1992, Locked-in syndrome after intrathecal cytosine arabinoside therapy for malignant immunoblastic lymphoma, Cancer, 70, 2504, 10.1002/1097-0142(19921115)70:10<2504::AID-CNCR2820701019>3.0.CO;2-H
Vogel, 1993, Filamentous degeneration of neurons: A possible feature of cytosine arabinoside neurotoxicity, Cancer, 71, 1303, 10.1002/1097-0142(19930215)71:4<1303::AID-CNCR2820710422>3.0.CO;2-6
Resar, 1993, Acute neurotoxicity after intrathecal cytosine arabi-noside in two adolescents with acute lymphoblastic leukemia of B-cell type, Cancer, 71, 117, 10.1002/1097-0142(19930101)71:1<117::AID-CNCR2820710119>3.0.CO;2-K
Moertel, 1964, Cerebellar ataxia associated with fluorinated pyrimidine therapy, Cancer Chemother. Rep., 41, 15
Piehl, 1964, Acute cerebellar syndrome secondary to 5-fluorouracil therapy, Neurology (Minneap), 14, 254
Gottlieb, 1971, Cerebellar ataxia with weekly 5-fluorouracil administration, Lancet, 1, 138, 10.1016/S0140-6736(71)90877-4
Boileau, 1971, Cerebellar ataxia during 5-fluorouracil (NSC-19893) therapy, Cancer Chemother. Rep., 55, 595
Diasio, 1988, Familial deficiency of dihydropyrimidine dehydrogenase, 81, 47
Atkins, 1991, High-dose 24-hour infusion of 5-fluorouracil in metastatic prostate cancer, 14, 526
Lynch, 1981, “Organic brain syndrome” secondary to 5-fluorouracil toxicity, Dis. Colon Rectum, 24, 130, 10.1007/BF02604302
Adams, 1984, Recurrent acute toxic optic neuropathy secondary to 5-fluorouracil [letter], Cancer Treat. Rep., 68, 565
Koenig, 1970, Biochemical basis for fluorouracil neurotoxicity, the role of Kreb's cycle inhibition by fluoroacetate, Arch. Neurol., 23, 155, 10.1001/archneur.1970.00480260061008
Cowan, 1980, Nerve conduction studies in patients treated with cis-diamminedichloroplatinum (II): A preliminary report, Cancer Treat. Rep., 64, 1119
Ashraf, 1983, Cisplatinum induced hypomagnesemia and peripheral neuropathy, Gynecol. Oncol., 16, 309, 10.1016/0090-8258(83)90156-7
Ozols, 1983, Treatment of poor prognosis nonseminomatous testicular cancer with a “high dose” platinum combination chemotherapy regimen, Cancer, 51, 1803, 10.1002/1097-0142(19830515)51:10<1803::AID-CNCR2820511008>3.0.CO;2-F
Thompson, 1984, Cisplatin neuropathy, 54, 1269
Roelofs, 1984, Peripheral sensory neuropathy and cisplatin chemotherapy, Neurology, 34, 934, 10.1212/WNL.34.7.934
Ongerboer de Visser, 1985, Polyneuropathy induced by cisplatin, Prog. Exp. Tumor Res., 29, 190, 10.1159/000411639
Mollman, 1988, Cisplatin neuropathy: Risk factors, prognosis, and protection by WR-2721, Cancer, 61, 2192, 10.1002/1097-0142(19880601)61:11<2192::AID-CNCR2820611110>3.0.CO;2-A
Hansen, 1989, Long-term neurotoxicity in patients treated with cisplatin, vinblastine, and bleomycin for metastatic germ cell cancer, J. Clin. Oncol., 7, 1457, 10.1200/JCO.1989.7.10.1457
Gerritsen van der Hoop, 1990, Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin, Cancer, 66, 1697, 10.1002/1097-0142(19901015)66:8<1697::AID-CNCR2820660808>3.0.CO;2-G
Boogerd, 1990, Cisplatin induced neuropathy: central, peripheral and autonomic nerve involvement, J. Neuro. Oncol., 9, 255, 10.1007/BF02341156
Mollman, 1988, Unusual presentation of cis-platinum neuropathy, Neurology, 38, 488, 10.1212/WNL.38.3.488
Grunberg, 1989, Progressive paresthesias after cessation of therapy with very high-dose cisplatin, Cancer Chemother. Pharmacol., 25, 62, 10.1007/BF00694340
Foman, 1990, Recent studies on neurotoxicity and on the epidemiology of brain and nervous system tumors, Curr. Opin. Oncol., 2, 691, 10.1097/00001622-199008000-00007
Stoter, 1989, Ten years survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin, J. Clin. Oncol., 7, 1099, 10.1200/JCO.1989.7.8.1099
Kedar, 1978, Peripheral neuropathy as a complication of cisdichlorodiammineplatinum (II) treatment: A case report, Cancer Treat. Rep., 62, 819
Hadley, 1979, Peripheral neuropathy associated with cis- dichloro-diammineplatinum (II) treatment, Cancer, 44, 2026, 10.1002/1097-0142(197912)44:6<2026::AID-CNCR2820440610>3.0.CO;2-1
Riggs, 1988, Prospective nerve conduction studies in cisplatin therapy, Ann. Neurol., 23, 92, 10.1002/ana.410230116
Dewar, 1986, Cisplatin neuropathy with Lhermitte's sign, J. Neurol. Neurosurg. Psychiatry, 49, 96, 10.1136/jnnp.49.1.96
Walther, 1987, The development of Lhermitte's sign during cisplatin chemotherapy, Cancer, 60, 2170, 10.1002/1097-0142(19871101)60:9<2170::AID-CNCR2820600909>3.0.CO;2-N
Elderson, 1989, Vibration perception and thermoperception as quantitative measurements in the monitoring of cisplatin induced neurotoxicity, J. Neurol. Science, 93, 167, 10.1016/0022-510X(89)90187-1
Hansen, 1990, Autonomic neuropathy after treatment with cisplatin, vinblastine, and bleomycin for germ cell cancer, BMJ, 300, 511, 10.1136/bmj.300.6723.511
Rosenfeld, 1984, Cisplatin-induced autonomic neuropathy, Cancer Treat. Rep., 68, 659
Walsh, 1982, Neurotoxic effects of cisplatin therapy, Arch. Neurol., 39, 719, 10.1001/archneur.1982.00510230045013
Schaefer, 1985, Ototoxicity of low- and moderate-dose cisplatin, Cancer, 56, 1934, 10.1002/1097-0142(19851015)56:8<1934::AID-CNCR2820560807>3.0.CO;2-F
Aguilar-Markulis, 1981, Auditory toxicity effects of long-term cis-dichlorodiammineplatinum (II) therapy in genitourinary cancer patients, J. Surg. Oncol., 16, 111, 10.1002/jso.2930160203
Vermorken, 1983, Ototoxicity of cisdiamminedichloroplatinum (II): influence of dose, schedule and mode of administration, Eur. J. Cancer Clin. Oncol., 19, 53, 10.1016/0277-5379(83)90398-X
Pollera, 1988, Very high-dose cisplatin-induced ototoxicity: a preliminary report on early and long-term effects, Cancer Chemother. Pharmacol., 21, 61, 10.1007/BF00262741
Cattaneo, 1988, Transient blindness and seizure associated with cisplatin therapy, J. Cancer. Res. Clin. Oncol., 114, 528, 10.1007/BF00391507
Berman, 1980, Seizures and transient cortical blindness associated with cisplatinum (II) diaminedichloride (PDD) therapy in a thirty-year old man, Cancer, 45, 764, 10.1002/1097-0142(19800215)45:4<764::AID-CNCR2820450425>3.0.CO;2-G
Gregg, 1992, Cisplatin neurotoxicity: The relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity, J. Clin. Oncol., 10, 795, 10.1200/JCO.1992.10.5.795
Von Hoff, 1979, Demyelination of peripheral nerves associated with cis-diammine-dichloroplatinum (II) (DDP) therapy, 20, 91
Castello, 1990, High-dose carboplatin in combination with etoposide (JET regimen) for childhood brain tumors, Am. J. Pediatr. Hematol. Oncol., 12, 297, 10.1097/00043426-199023000-00008
Castello, 1990, A pilot study of high-dose carboplatin and pulsed etoposide in the treatment of childhood solid tumors, Pediatr. Hematol. Oncol., 7, 129, 10.3109/08880019009033382
Green, 1990, Carboplatin therapy in advanced endometrial cancer, Obstet Gynecol, 75, 696
Thatcher, 1990, Carboplatin in small cell lung cancer, Semin. Oncol., 17, 40
Extra, 1990, Phase I study of oxaliplatin in patients with advanced cancer, Cancer Chemother. Pharmacol., 25, 299, 10.1007/BF00684890
Sutton, 1989, Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study, J. Clin. Oncol., 7, 1672, 10.1200/JCO.1989.7.11.1672
Antman, 1989, Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma, J. Clin. Oncol., 7, 126, 10.1200/JCO.1989.7.1.126
Heim, 1981, Central nervous side effects following ifosfamide monotherapy of advanced renal carcinoma, J. Cancer Res. Clin. Oncol., 100, 113, 10.1007/BF00405909
Curtin, 1991, Ifosfamideinduced neurotoxicity, Gynecol. Oncol., 42, 193, 10.1016/0090-8258(91)90344-5
Pratt, 1990, Ifosfamide neurotoxicity is related to previous cisplatin treatment for pediatric solid tumors, J. Clin. Oncol., 8, 1399, 10.1200/JCO.1990.8.8.1399
Pratt, 1987, Phase II trial of ifosfamide in children with malignant solid tumors, Cancer Treat. Rep., 71, 131
Kellie, 1987, Ifosfamide neurotoxicity in children [letter], J. Clin. Oncol., 5, 512, 10.1200/JCO.1987.5.3.512
Pratt, 1986, Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna, J. Clin. Oncol., 4, 1253, 10.1200/JCO.1986.4.8.1253
Pratt, 1989, Ifosfamide in pediatric malignant solid tumors, Cancer Chemother. Pharmacol., 24, S24, 10.1007/BF00253234
Cerny, 1989, A simple outpatient treatment with oral ifosfamide and oral etoposide for patients with small cell lung cancer, Br. J. Cancer., 60, 258, 10.1038/bjc.1989.265
Elias, 1990, High-dose ifosfamide with mesna uroprotection: A phase I study, J. Clin. Oncol., 8, 170, 10.1200/JCO.1990.8.1.170
Danesh, 1989, Ifosfamide encephalopathy, J. Toxicol. Clin. Toxicol., 27, 293, 10.3109/15563658908994426
Anderson, 1991, Ifosfamide extrapyramidal neurotoxicity, Cancer, 68, 72, 10.1002/1097-0142(19910701)68:1<72::AID-CNCR2820680114>3.0.CO;2-#
Goren, 1986, Dechloroethylation of ifosfamide and neurotoxicity [letter], Lancet, 2, 1219, 10.1016/S0140-6736(86)92227-0
Ohnuma, 1970, Biochemical and pharmacological studies with asparaginase in man, Cancer Res., 30, 2297
Phillips, 1983, Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC 4366650 and cryopreserved autologous marrow transplantation for refractory cancer, Cancer, 52, 1792, 10.1002/1097-0142(19831115)52:10<1792::AID-CNCR2820521006>3.0.CO;2-D
Takvorian, 1983, Autologous bone marrow transplantation, 1, 610
Bonomi, 1979, Phase II trial of hexamethylmelamine in ovarian carcinoma resistent to alkylating agents, Cancer Treat. Rep., 63, 137
Denefrio, 1978, Phase II study of hexamethylmelamine in women with advanced breast cancer refractory to standard cyto-toxic therapy, Cancer Treat. Rep., 62, 173
Wolff, 1990, High-dose N,N′,N″-Triethylenethiophosphoramide (Thiotepa) with autologous bone marrow transplantation: Phase I studies, Semin. Oncol., 17, 2
Rowinsky, 1992, Taxol: The first of taxanes, an important new class of antitumor agents, Semin. Oncol., 19, 646
Masurovsky, 1981, Microtubule arrays in taxol treated mouse root ganglia-spinal cord cultures, Brain Res., 217, 392, 10.1016/0006-8993(81)90017-2
Masurovsky, 1983, Morphologic alterations in dorsal root ganglion neurons and supporting cells of organotypic mouse spinal cord-ganglion cultures exposed to taxol, Neuroscience, 10, 491, 10.1016/0306-4522(83)90148-3
Wiernik, 1987, Phase I clinical and pharmacokinetic study of taxol, Cancer Res., 47, 2486
Lipton, 1989, Taxol produces a predominantly sensory neuropathy, Neurology, 39, 368, 10.1212/WNL.39.3.368
New, 1993, Neurotoxicity of Taxotere, 34, 1393
Chun, 1986, Central nervous system toxicity of fludarabine phosphate, Cancer Treat. Rep., 70, 1225
Merkel, 1986, Central nervous system toxicity with fludarabine, Cancer Treat. Rep., 70, 1449
Warrell, 1986, Phase I and II study of fludarabine phosphate in leukemia: Therapeutic efficacy with delayed central nervous system toxicity, J. Clin. Oncol., 4, 74, 10.1200/JCO.1986.4.1.74
Spriggs, 1986, Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: Phase I and neuropathological study, Cancer Res., 46, 5953
Cohen, 1993, Reversible neurologic toxicity in patients treated with standard-dose fludarabine phosphate for mycosis fungoides and chronic lymphocytic leukemia, Ann. Intern. Med., 118, 114, 10.7326/0003-4819-118-2-199301150-00007
Myers, 1992, Suramin: A novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer, J. Clin. Oncol., 10, 881, 10.1200/JCO.1992.10.6.881
Eisenberger, 1993, Phase I/II trial of suramin in hormone-refractory prostate cancer: Evidence of anti-tumor activity over a broad range of plasma suramin concentrations, 12, 776
De Koning, 1987, Org 2766 protects from cisplatin-induced neurotoxicity in rats, Exp. Neurol., 97, 746, 10.1016/0014-4886(87)90132-4
Gerritsen van der Hoop, 1988, Efficacy of the neuropeptide Org. 2766 in the prevention and treatment of cisplatininduced neurotoxicity in rats, Eur. J. Cancer Clin. Oncol., 24, 637, 10.1016/0277-5379(88)90293-3
Gerritsen van der Hoop, 1990, Prevention of cisplatin neurotoxicity with an ACTH(4–9) analoque in patients with ovarian cancer, N. Engl. J. Med., 322, 89, 10.1056/NEJM199001113220204
Glover, 1987, WR-2721 and high-dose cisplatin, 5, 574
Kish, 1991, Evaluation of high dose WR 2721 +high dose cisplatin+5-fluorouracil infusion in recurrent/metastatic head and neck cancer, 10, 681
Ewing, 1986, Autonomic neuropathy: Its diagnosis and prognosis, Clin. Endocrinol. Metab., 15, 855, 10.1016/S0300-595X(86)80078-0
Nielsen, 1972, The peripheral nerve function in chronic renal failure, IV, 191, 287